A research program that's paying cash to people who inject drugs is raising concerns for some residents and business owners.

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...

Continuing their journey to develop a vaccine for HIV, Oregon Health & Science University researchers have identified a gene ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention ... reduce new infections here,” she told SciDev.Net. The drug’s twice-yearly ...

as it can significantly reduce new infections of HIV. 2 However, ADR and transmitted drug resistance (TDR) are possible given the encouragement to begin ART early. An increased number of countries ...

The BRAAVE2020 study investigated the efficacy of switching Black Americans living with HIV to a B/F/TAF single-pill regimen.

It is good news for millions of Kenyans living with HIV/AIDS as Kenya will start buying new highly-effective antiretroviral drugs at much lower prizes following an international price deal.

Experts And Viewpoints, October 02, 2006 An Expert Interview With Dr. Cal Cohen Recent approvals of new HIV drugs and a rich ... comparison of commercial phenotypic tests, and more.

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

While most populations cannot afford the available HIV drugs, health professionals in North America continue incorporating new HIV drugs into health care to improve patient conditions. Europe is ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial ... charge related to its 2020 ...